Innate Pharma Reports Q3 Revenue Growth and Outlines 2027 Pipeline Milestones
Innate Pharma (IPHA) reported a rise in nine-month revenue to €3.4 million, up from €2.3 million during the same period last year. As of September 30, 2026, the company holds €96.8 million in cash, cash equivalents, and financial assets. This liquidity position was bolstered by a $75 million upfront payment related to a transaction with Sobi and proceeds from a recent €30 million private placement. The company has outlined its strategic roadmap through 2027, focusing on key pipeline milestones to drive future growth.
Topics: cash runway partnership proceeds private placement revenue growth